glp-1 therapy mandeville Weekly Rundown: gene enters first human trial Tirzepatide Weight Loss Injections &

Q2: Why is GHK-Cu associated with skin and wound-healing research

doi:10.1177/0091270010389471 164

Meister, I

GLP-1 RAs may address this directly Tirzepatide (dual GIP/GLP-1) appears to achieve the greatest weight reduction (1624% in non-diabetic patients) GLP-1 RAs may reduce or enable tapering of systemic immunosuppressants (including methotrexate and biologics) in patients who achieve significant weight loss, reducing cumulative toxicity

Lillys therapy set a new benchmark for obesity treatment: in the first head-to-head trial comparing the two obesity therapies, Zepbound achieved an average weight loss of 20.2% versus 13.7% for Wegovy after 72 weeks